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ABSTRACT
High mobility group box 1 (HMGB1) is a non-histone protein localised in the cell nucleus, where it interacts
with DNA and promotes nuclear transcription events. HMGB1 levels are elevated during acute myeloid
leukaemia (AML) progression followed by participation of this protein in triggering signalling events in
target cells as a pro-inﬂammatory stimulus. This mechanism was hypothesised to be employed as a
survival pathway by malignant blood cells and our aims were therefore to test this hypothesis
experimentally. Here we report that HMGB1 triggers the release of tumour necrosis factor alpha (TNF-a) by
primary human AML cells. TNF-a induces interleukin 1 beta (IL-1b) production by healthy leukocytes,
leading to IL-1b-induced secretion of stem cell factor (SCF) by competent cells (for example endothelial
cells). These results were veriﬁed in mouse bone marrow and primary human AML blood plasma samples.
In addition, HMGB1 was found to induce secretion of angiogenic vascular endothelial growth factor
(VEGF) and this process was dependent on the immune receptor Tim-3. We therefore conclude that
HMGB1 is critical for AML progression as a ligand of Tim-3 and other immune receptors thus supporting
survival/proliferation of AML cells and possibly the process of angiogenesis.
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High mobility group box 1 (HMGB1) is a non-histone protein
localised in the nucleus, where it binds DNA in order to pro-
mote nuclear transcription processes.1 In addition, HMGB1
was recently found to function as a damage-associated molec-
ular pattern (DAMP) when released passively from either
dead, dying/injured cells or secreted by immune/cancer cells
in response to endogenous and/or exogenous stimuli, such as
hypoxia, endotoxin etc..2-4 This process is followed by partici-
pation of HMGB1 in triggering signalling events in target
cells.1-4 Therefore, it is often called “alarmin” in order to
reﬂect its function as a factor secreted by cells affected by a
stressor.1 It has recently been found that HMGB1 levels are
signiﬁcantly elevated during acute myeloid leukaemia (AML,
blood/bone marrow cancer).5,6 Moreover, AML cells were
shown to express high levels of HMGB1.5,6 Elevated levels of
secreted HMGB1 associated with AML progression are likely
to be caused by a combination of increased expression of this
protein in AML cells and conditions supporting its secretion
such as hypoxia and death of the cells in the tumour microen-
vironment.5-7
Upon release, HMGB1 can interact with several immune
receptors, including Toll-like receptors 2 and 4 (TLRs 2 and
4) as well as receptor of advanced glycation end products
(RAGE).8 Recent evidence has suggested a possible interac-
tion of HMGB1 with the immune receptor Tim-3 (T cell
immunoglobulin and mucin domain 3) which is highly
expressed in human acute myeloid leukaemia (AML) cells.1,2
However, the role of HMGB1 in leukaemia progression
remains unstudied. Interestingly, signalling pathways trig-
gered by TLRs 2/4, RAGE and Tim-3 include activation of the
phosphatidylinositol-3 kinase (PI-3 K)/mammalian target of
rapamycin (mTOR) pathway, which directly controls initia-
tion of translation of proteins crucial for cell survival as well
as cytokines including tumour necrosis factor a (TNF-a), a
pleiotropic inﬂammatory cytokine participating in a variety of
physiological processes associated with control of host
immune defence and respectively haematopoiesis.9-14 This
pathway also triggers accumulation of hypoxia-inducible fac-
tor-1 a (HIF-1a), an inducible subunit of HIF-1 transcription
complex, which induces glycolysis and angiogenesis on
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genomic level.9,12 However, the effects of HMGB1 on signal-
ling events described above remain hypothetic and are not
comprehensively or conceptually studied yet.
Here we report for the ﬁrst time that HMGB1 triggers the
release of TNF-a by primary human AML cells independently
of Tim-3. TNF-a induces interleukin 1 beta (IL-1b) production
by healthy leukocytes and subsequent IL-1b-induced secretion
of stem cell factor (SCF) by competent cells (for example endo-
thelial cells). Treatment of mouse bone marrow cells with
HMGB1 led to signiﬁcant increase in TNF-a, IL-1b and SCF
production. The levels of TNF-a, IL-1b and SCF in blood
plasma of AML patients were also signiﬁcantly upregulated in
comparison to healthy individuals. SCF, a ligand of the Kit
growth factor receptor is required for survival and proliferation
of AML cells. We also show that HMGB1 induces the secretion
of angiogenic protein vascular endothelial growth factor
(VEGF) and this process is controlled by Tim-3. Synchrotron
radiation circular dichroism (SRCD) spectroscopy conﬁrmed
that HMGB1 can speciﬁcally bind Tim-3. We conclude that
HMGB1 as an alarmin participates in AML progression by
interacting with Tim-3 and other immune receptors thus sup-
porting the survival/proliferation of AML cells and possibly the
process of angiogenesis.
Materials and methods
Materials
RPMI-1640 medium, foetal bovine serum, supplements as well
as basic laboratory chemicals were purchased from Sigma (Suf-
folk, UK). MaxisorpTM microtitre plates were obtained from
Nunc (Roskilde, Denmark) and Oxley Hughes Ltd (London,
UK). Mouse monoclonal antibodies directed against HIF-1a,
mTOR and b-actin, as well as rabbit polyclonal antibodies
against phospho-S2448 mTOR, RAGE and HRP-labelled rabbit
anti-mouse secondary antibody were purchased from Abcam
(Cambridge, UK). Antibodies against phospho-S65 and non-
phosphorylated (total) eukaryotic initiation factor 4E binding
protein 1 (eIF4E-BP1) were obtained from Cell Signaling Tech-
nology (Danvers, MA USA). Goat anti-mouse and goat anti-
rabbit ﬂuorescence dye-labelled antibodies were obtained from
LI-COR (Lincoln, Nebraska USA). ELISA-based assay kits for
the detection of TNFa, IL-1b, SCF and VEGF were purchased
from Bio-Techne (R&D Systems, Abingdon, UK). Anti-Tim-3
mouse monoclonal antibody, its single chain variant as well as
human Ig-like V-type domain of Tim-3 (amino acid residues
22–124) and human HMGB1 expressed and puriﬁed from E.
coli (see below for more details) were used in our experi-
ments.11,15 All other chemicals purchased were of the highest
grade of purity commercially available.
Cell lines and primary cells
THP-1 human myeloid leukemia monocytes and MCF-7 epi-
thelial breast cancer cells were obtained from the European
Collection of Cell Cultures (Salisbury, UK). Cells were cultured
in RPMI 1640 medium (R8758 – Sigma (Suffolk, UK) with L-
glutamine and sodium bicarbonate, liquid, sterile-ﬁltered, suit-
able for cell culture) supplemented with 10% foetal bovine
serum, penicillin (50 IU/ml) and streptomycin sulphate
(50 mg/ml).
Primary human AML mononuclear blasts (AML-PB001 F,
newly diagnosed/untreated) were purchased from AllCells
(Alameda, CA, USA) and handled in accordance with the man-
ufacturer’s instructions following ethical approval (REC refer-
ence: 16-SS-033).
Bone marrow was isolated from femur bones of six-week-
old C57 BL16 mice (25 § 2.5 g, kindly provided by Dr. Gurprit
Lall, School of Pharmacy, University of Kent) which were used
for the experiments following approval by the Institutional
Animal Welfare and Ethics Review Body. Animals were han-
dled by authorised personnel in accordance with the Declara-
tion of Helsinki protocols. Bone marrow was isolated from
femur bone heads as described before.15,16 Cells were kept in
RPMI 1640 medium supplemented with 10% foetal bovine
serum, penicillin (50 IU/ml) and streptomycin sulphate
(50 mg/ml).
Primary human blood plasma samples
Blood plasma from healthy donors was obtained from buffy coat
blood (which originated from donors undergoing routine blood
donation) provided by the National Health Blood and Transfu-
sion Service (NHSBT, UK) following ethical approval (REC ref-
erence: 16-SS-033). Primary human AML plasma samples were
obtained from the sample bank of University Medical Centre
Hamburg-Eppendorf (Ethik-Kommission der €Arztekammer
Hamburg, reference: PV3469).
HMGB1 puriﬁcation
HMGB1 was produced and puriﬁed from E. Coli Rosetta DE2
competent. Cells were grown at 37C in LB medium and har-
vested 3 hours after induction with isopropyl b-D-1-thiogalac-
topyranoside (IPTG) at OD600 0.7. The pellet was collected by
centrifugation, re-suspended and sonicated on ice with 5 £ 30
seconds of pulsing and 30 seconds rest (buffer contained
20 mM TrisHCl pH 8; 150 mM NaCl; 10 mM imidazole; 2
Beta-SH and 0.2% Triton X100). Following high-speed centri-
fugation, HMGB1 containing supernatant was subjected to Ni-
afﬁnity and size exclusion chromatography. The protein was
then eluted at a volume consistent with monomeric HMGB1.
After size exclusion HMGB1 was passed through an anion
exchange (Q) column to ensure LPS removal, eluted in sodium
phosphate buffer with 1.5M NaCl and ﬁnally dialysed exten-
sively (at least 36 hours) against PBS buffer. Absence of LPS
contamination was conﬁrmed using mammalian cell lines.
HMGB1 protein was prepared for structural studies and
hence highly pure. It was routinely tested for size and degrada-
tion by size exclusion (during puriﬁcation) and dynamic light
scattering (ﬁnal product). Sample concentration was deter-
mined by UV spectroscopy. Proper folding was controlled by
NMR and CD spectroscopy (all samples required a CD spec-
trum equivalent to that of the samples characterised with bidi-
mensional 15 N NMR spectroscopy). This protein displayed
activity similar to the human recombinant protein expressed in
HEK293 cells obtained from Sigma (Suffolk, UK, SRP6265, as
veriﬁed using THP-1 and primary human AML cells). The
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ability of HMGB1 to interact with TLRs seen in our experi-
ments conﬁrmed similarities in the redox state of preparations
used in our work in comparison to the pro-inﬂammatory form
of HMGB1 released by dead/dying or stressed cancer/immune
and other cells.
Western blot analysis
Tim-3, HIF-1a, phospho-S65 and total eIF4E-BP1 as well as
RAGE were analysed using Western blot.13,14 b-actin stain-
ing was used to conﬁrm equal protein loading as described
previously. LI-COR goat secondary antibodies (dilution
1:2000), conjugated with ﬂuorescent dyes, were used in
accordance with manufacturer’s protocol to visualise target
proteins (using a LI-COR Odyssey imaging system). West-
ern blot data were quantitatively analysed using Odyssey
software and values were subsequently normalised against
those of b-actin. In order to quantitate levels of mTOR-
dependent phosphorylation of eukaryotic initiation factor 4
E binding protein 1 (eIF4E-BP), we measured phospho-S65-
eIF4E-BP and total quantity of eIF4E-BP on a different
membrane to avoid the inﬂuence of possible incomplete
membrane stripping following quantitative analysis. Values
were normalised against those of b-actin for corresponding
membranes. The ratio between normalised phospho-S65-
eIF4E-BP and total eIF4E-BP was calculated in order to
characterise eIF4E-BP phosphorylation levels. The following
equation was implemented:
pS65¡ eIF4E¡BP level D pS65¡ eIF4E¡BP½ 
Actin½ 
 ½eIF4E¡BP total
Actin½ 
This ratio in control samples was considered as 100%.
Enzyme-linked immunosorbent assays (ELISAs)
Human or mouse TNF-a, IL-1b, SCF as well as human VEGF,
either in cell culture media or human blood plasma were mea-
sured by ELISA using R&D Systems kits according to manufac-
turer’s protocols. Phosphorylation of mTOR was analysed by
ELISA as previously described.13
In cell assays and in cell Westerns
We employed a standard LI-COR in-cell Western (ICW)
assay (methanol was used as permeabilization agent) to
characterise Tim-3 total levels in studied cells. The in-cell
(ICA, also called on-cell) assay was employed to detect
Tim-3 surface presence in the cells. Following washing with
PBS, cells were scanned using a LI-COR Odyssey imaging
system.17
Detection of PI-3K activity
PI-3K activity was measured in cell lysates as described
previously.18 Brieﬂy, cell lysates were incubated with 30 ml
0.1 mg/ml substrate (PI-4,5-diphosphate emulsion) in kinase
assay buffer. The latter was prepared from 20 mM Tris (pH
7.5), 100 mM NaCl, 0.5 mM EDTA, 8 mM MgCl2 and
40 mM ATP in a total volume of 100 ml at 37C with con-
stant agitation. Reactions were terminated by adding 1 ml of
hexane/isopropanol (13:7, v:v) mixture and 0.2 ml of a mix-
ture of 2 M KCl/HClconc (8:0.25, v:v). After vortexing the
organic phases were washed with HCl (0.5 ml; 0.1 M). This
was followed by detection of phosphate groups using a col-
orimetric assay. The values obtained in the control samples
of each experiment per 1 mg protein were counted as 100%
of the PI-3 K activity. Other values were normalised and
expressed as % control.
Synchrotron radiation circular dichroism (SRCD)
spectroscopy
Human recombinant Tim-3 and HMGB-1, either alone or
in combination, were analysed using SRCD spectroscopy at
beamline B23, Diamond Light Source (Didcot, UK). B23,
equipped with a highly collimated microbeam, allows for
the use of a small aperture long path length microcuvette
which is unattainable with benchtop instruments due to
divergent beams since samples available are of very low
volume and concentrations. SRCD measurements were per-
formed using 0.2 mM of samples in a 1 cm path length cell
of 3 mm aperture diameter and 60 ml capacity using a
Module B instrument with a 1 nm increment, 1 s integra-
tion time, 1.2 nm bandwidth at 23 C.19-24 Temperature
denaturation measurements were collected over the temper-
atures 20C – 95C (in 5C increments) for HMGB1, Tim-
3 and the 1:1 mixture. The results obtained were processed
using CDApps25 and OriginPro. For thermal denaturation
measurements, change in CD (mdeg) at a speciﬁc wave-
length was plotted against the corresponding temperature
for ﬁtting using the Gibbs-Helmholtz equation derived
from Boltzmann distribution,26,27 sigmoidal two-state dena-
turation curve to a Boltzmann distribution and the expres-
sion modiﬁed to include parameters for ﬁtting of thermal
denaturation data for the calculation of the melting tem-
perature (Tm). Titration experiments were conducted as
described for standard far-UV measurements, with the
modiﬁcation of measurements collected after the addition
of incremental volumes of Tim-3 stock as described previ-
ously.28 The change of CD (mdeg) at single wavelength
was plotted against respective ligand concentration (mM)
using OriginPro and ﬁtted with the Hill binding29 func-
tion to determine the Kd for binding.
Statistical analysis
Each ELISA and cell experiment was performed at least three
times and statistical analysis when comparing two events at a
time was conducted using a two-tailed Student’s t-test. Multiple
comparisons were performed using an ANOVA test. Post-hoc
Bonferroni correction was applied. Statistical probabilities (p)
were expressed as  where p < 0.05; , p < 0.01 and  when p
< 0.001.
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Results
HMGB1 induces moderate activation of PI3-K/mTOR
pathway, TNF-a and VEGF secretion in human AML cells
We used monocytic THP-1 human acute myeloid leukaemia
cells which express Tim-3, but keep most of it inside the cell
(Fig. 1 left panel), and primary human AML cells (AML-
PB001F) where most Tim-3 is expressed on the cell surface
(Fig. 1 right panel). Cells were exposed for 4 h to 1 mg/ml
HMGB1 with or without 1 h pre-treatment with single-chain
antibody against Tim-3, which does not display Tim-3 agonis-
tic properties and also prevents the interaction of other ligands
with it. We found that HMGB1 induced activation of PI-3K in
both THP-1 and primary human AML cells. In both cell types
this effect was non-signiﬁcantly downregulated by the presence
of anti-Tim-3 antibody (Fig. 1). This was consistent with a
moderate activation of mTOR (phosphorylation at S2448) and
increased phosphorylation of mTOR substrate eukaryotic initi-
ation factor 4 E binding protein 1 (eIF4E-BP1). Increased TNF-
a secretion took place in both cases. Neither process observed
was inﬂuenced by the presence of anti-Tim-3 antibody, sug-
gesting that the effects observed are Tim-3-independent.
Pre-treatment of THP-1 cells for 1 h with 2 mg/ml neutralis-
ing antibodies directed against TLR2, TLR4 and RAGE
Figure 1. Differential receptors are involved in HMGB1-induced biological responses of human AML cells. Total levels of the immune receptor Tim-3 and its surface pres-
ence were characterised in THP-1 and primary human AML-PB001F cells by in-cell Western (ICW) and in-cell (on-cell) assay (ICA) respectively (see Materials and Methods
for details). Both cell types were exposed to 1 mg/ml HMGB1 for 4 h with or without 1 h pre-treatment with single chain anti-Tim-3 antibody (aTim-3 (-)) followed by
Western blot analysis of phospho-S65 vs total eIF4E-BP1, HIF-1a and RAGE expression as well as by detection of phospho-S2448 mTOR, release of TNF-a and VEGF using
ELISA. PI-3 K activity was monitored by colorimetric assay. Images are from one experiment representative of ﬁve which gave similar results. Data is shown as mean values
§ SEM of ﬁve independent experiments.  p < 0.05; , p < 0.01 and  when p < 0.001 vs control; a p < 0.05; aa, p < 0.01 vs HMGB1.
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followed by 4 h of exposure to 1 mg/ml HMGB1 showed that
TLRs 2 and 4, but not RAGE, are involved in HMGB1-induced
TNF-a secretion (Supplementary Fig. 1). However, it does not
rule out the fact that during long-term exposure RAGE might
contribute to HMGB1-induced intracellular TNF-a expression
which can be upregulated by RAGE ligands30
Consequently, we detected the activation of HIF-1a accu-
mulation in THP-1 cells but not in AML cells which had
high background levels of HIF-1a and thus probably did
not respond to HMGB1 treatment (Fig. 1). In both cell
types, however, we observed a signiﬁcant increase in VEGF
secretion (Fig. 1) which was signiﬁcantly reduced (but not
HIF-1a accumulation as seen from either Western blot data
or intracellular VEGF levels (this was veriﬁed by ELISA
performed on the cell lysates – data not shown)) by the
presence of anti-Tim-3 antibody. The level of downregula-
tion was proportional to the amount of Tim-3 present on
the surface of each cell type. THP-1 and primary AML cells
express TLRs 2 and 4. They also express high levels of
RAGE, as veriﬁed by Western blot analysis (Fig. 1), which
suggests that HMGB1 induces activation of the PI-3K/
mTOR pathway and HIF-1a accumulation as well as TNF-
a secretion through classic immune receptors like TLRs2/4,
and RAGE, while secretion of VEGF is a Tim-3-dependent
process.
Characterisation of HMGB1-Tim-3 interactions in vitro
We then sought to obtain conﬁrmation of direct interac-
tions between HMGB1 and Tim-3 using the recombinant,
puriﬁed Ig-like V-type domain of human Tim-3 (residues
22–124) and human HMGB1. We employed SRCD spec-
troscopy for both qualitative and quantitative binding
assays. Titration of 200 nM HMGB1 with increasing
amounts of Tim-3 (Fig. 2A) indicated a high nanomolar
binding afﬁnity (Kd D 10¡7 M). The SRCD spectrum of a
1:1 HMGB1-Tim-3 complex appeared different from the
sum of the SRCD spectra of the individual components
(Fig. 2B), suggesting the presence of conformational rear-
rangements upon formation of the complex. Far UV ther-
mal denaturation studies were also performed on the
complex, further supporting the above data (Supplementary
Figs. 2 and 3).
HMGB1 induces TNF-a secretion by human AML leading
to upregulation of SCF production
Since it was obvious that both the AML cell line (THP-1) and
primary AML cells secreted TNF-a in response to stimulation
with HMGB1, we studied the effects of released TNF-a on the
production of IL-1b by primary healthy human leukocytes
(PHL). Cell culture medium obtained after stimulation of
THP-1 cells with 1 mg/ml HMGB1 was used to treat primary
healthy leukocytes for 4 h with or without 1 h pre-treatment
with 2 mg/ml TNF-a-neutralising antibody. We found that in
the absence of TNF-a-neutralising antibody, PHL released IL-
1b, while in the presence of TNF-a-neutralising antibody PHL
did not release detectable amounts of IL-1b. Medium contain-
ing IL-1b was used to culture MCF-7 breast cancer epithelial
cells (these cells express IL-1 receptor type 1 and are capable of
releasing stem cell factor (SCF)) for 24 h in the absence or pres-
ence of 2 mg/ml of IL-1b-neutralising antibody. We found that,
in the presence of IL-1b-neutralising antibody, MCF-7 did not
release detectable amounts of SCF, while in the absence of it
SCF release was clearly detectable. These results (all shown in
Fig. 3A) suggest that HMGB1 induces the release of TNF-a by
AML cells. TNF-a induces IL-1b secretion by PHL. Released
IL-1b stimulates the production of SCF by endothelial/epithe-
lial cells. SCF is required for proliferation of AML cells and
thus supports leukaemia progression.
We sought to obtain conﬁrmation of this biological test
using mouse bone marrow cells ex vivo. Mouse bone marrow
cells were exposed to 1 mg/ml HMGB1 for 24 h. We observed
that the levels of secreted TNF-a, IL-1b and SCF were signiﬁ-
cantly increased compared to non-treated bone marrow cells
(Fig. 3B) and that the ratio between these cytokines was similar
to that observed in the biological test shown in Fig. 3A.
We then measured the levels of TNF-a, IL-1b and SCF in
the blood plasma of 10 healthy human donors and 45 AML
patients. We found that the levels of all three factors were sig-
niﬁcantly increased (Fig. 3C – I). There was a clear evidence of
correlation between IL-1b vs TNF-a, SCF vs IL-1b and SCF vs
Figure 2. Interaction of HMGB1 and the immune receptor Tim-3. Interaction of HMGB1 protein with Tim-3 was analysed using SRCD spectroscopy-based titration which
was conducted in the far UV region using 0.2 mM HMGB1 and increasing stoichiometric concentrations of Tim-3 (A). Changes in CD signal monitored at 222 nm were plot-
ted against Tim 3 concentration using Hill function. Qualitative binding was veriﬁed by analysis of interactions of equimolar concentrations of Tim-3 and HMGB1 using
SRCD spectroscopy (B).
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TNF-a (Fig. 3C and Supplementary Fig. 4) in the blood plasma
of both healthy donors and AML patients which contained
detectable amounts of all the studied cytokines/SCF suggesting
that there is a link between these three factors regardless of the
presence of HMGB1. But the increase in all three factors sug-
gests that HMGB1 activates this intercellular cascade in order
to increase the levels of secreted SCF thus supporting leukaemia
progression.
Discussion
HMGB1 is an “alarmin” which can be secreted by stressed and
dying cells as well as cancer and immune cells, and thus was
suggested to play a role in leukaemia progression.1-7 Recent evi-
dence demonstrated that HMGB1 can also act as a ligand of the
immune receptor Tim-3 which is highly expressed on the sur-
face of human AML cells.1,2 However, the signalling activity of
HMGB1 in AML cells has not been elucidated and was thus the
main aim of our work.
In both, a human AML cell line (THP-1 cells) and primary
AML cells (AML-PB001F) we demonstrated that HMGB1
upregulates the activity of the PI-3 K/mTOR pathway, thus
leading to increased TNF-a secretion and accumulation of
HIF-1a as well as VEGF release (Fig. 1). However, except
VEGF secretion (not HIF-1a-dependent expression), these
effects were not Tim-3-mediated since Tim-3 neutralising
single-chain antibody did not affect any of the processes
described above (except for VEGF release). Importantly,
non-differentiated THP-1 cells express moderate levels of
Tim-3 on their surface – this process has to be induced by
activation of PKCa (for example PMA or latrophilin 1
ligands).15 Primary AML cells which use Tim-3/galectin-9
pathway in order to escape immune attack express much
higher levels of Tim-3 protein on their surface. This differ-
ence was proportional to that in HMGB1-induced VEGF
release in THP-1 and primary AML cells. Furthermore, neu-
tralisation of Tim-3 led to attenuation of HMGB1-induced
VEGF secretion in both cases suggesting that this is a Tim-3-
mediated process.
Highly sensitive SRCD spectroscopic analysis of HMGB1-
Tim-3 interactions conﬁrmed that these two proteins interact
with each other speciﬁcally, but the apparent afﬁnity was
moderately high (Kd D 10¡7 M). This afﬁnity, however, can
be increased by glycosides which normally bind to Tim-3 (the
protein used in the studies was sugar-free). All these results
suggest that this interaction is probably rather more secretory
than a signal transduction event per se. Interestingly, the for-
mation of the protein complex was accompanied by an
increase in a-helical content at the expense of the b-strand
presumably arising mainly from the Tim-3 protein. Biological
tests demonstrated that TNF-a released from primary human
AML cells in an HMGB1-dependent manner is capable of
inducing IL-1b secretion by primary human healthy leuko-
cytes. This is in line with recent observations suggesting upre-
gulation of both TNF-a and IL-1b secretion in response to
stimulation with HMGB1.5,6 This reaction is a very important
step in AML progression since IL-1b interacts with IL-1
receptor type I and induces production and secretion of SCF
required for proliferation of AML cells. Human AML cells
express high levels of Kit receptor, which recognises SCF, and
Figure 3. HMGB1 induces an intercellular signalling cascade leading to SCF secretion. (A) Primary human AML cells (AML-PB-001F) were exposed for 4 h to HMGB1 fol-
lowed by collection of the culture medium (detection of TNF-a was performed in this medium using ELISA), which was used to culture primary human healthy leukocytes
for 4 h in the absence or presence of TNF-a-neutralising antibody. Medium was collected (levels of IL-1b were measured by ELISA) and used to culture MCF-7 breast can-
cer epithelial cells for 4 h in the absence or presence of IL-1b-neutralising antibody. Following this exposure, medium was collected and SCF was measured in it by ELISA.
(B) Primary mouse bone marrow cells (106 cells per 3 ml medium) were exposed for 24 h to 1 mg/ml HMGB1 followed by detection of TNF-a, IL-1b and SCF by ELISA.
(C – I). Levels of TNF-a, IL-1b and SCF were measured in the blood plasma of healthy donors and AML patients by ELISA. Mean values§ SEM are presented as well as lev-
els of each protein in blood plasma of each analysed donor/patient. p < 0.05; p < 0.01 vs control.
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this haematopoietic factor thus becomes highly oncogenic
since AML cells are capable of inducing SCF production by
healthy cells. The same effect was seen in primary mouse
bone marrow cells. When exposed to HMGB1, levels of TNF-
a, IL-1b and SCF increased suggesting that HMGB1 can, in
principle, induce this effect in bone marrow too. However,
production of HMGB1 is not observed in healthy bone mar-
row1,2 since there are not enough stressed/dying or injured
cells in order to produce it (in our samples over 95% of cells
were viable as determined by trypan blue exclusion, data not
shown). However, in leukaemic bone marrow this process is
likely to take place due to lack of oxygen and increased
HMGB1 expression in transformed cells.
Finally, we found that in blood plasma of AML patients, the
levels of TNF-a, IL-1b and SCF were signiﬁcantly higher com-
pared to blood plasma from healthy donors.
We therefore concluded that in human bone marrow
affected by AML, and respectively, by hypoxic conditions, cells
release HMGB1 which induces TNF-a production and subse-
quent secretion of IL-1b which stimulates SCF production/
secretion by endothelial cells. This SCF is used to further stimu-
late the survival/proliferation of AML cells. While these pro-
cesses are Tim-3-independent, HMGB-1 interacts with Tim-3
and induces VEGF secretion, which is required to induce
angiogenesis in bone marrow so that hypoxic conditions caused
by increasing AML cell numbers can be relieved. This mecha-
nism is summarised in the Fig. 4 (a more detailed scheme illus-
trating the possible interactions in the bone marrow is shown
in Supplementary Fig. 5).
HMGB1 has already been considered as a possible therapeu-
tic target for leukaemia treatment.7 Furthermore, targeting
HMGB1 has recently been shown to increase drug sensitivity in
AML.30 Our ﬁndings demonstrate additional insights that
HMGB1 could be considered as a possible therapeutic target in
AML and further conﬁrm the efﬁciency of targeting Tim-3
(here to speciﬁcally block AML-induced angiogenesis) in anti-
AML therapy.
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